Alexion, AstraZeneca Rare Disease Agreed To Purchase And License An Agreement For A Portfolio Of Preclinical Gene Therapy Programs From Pfizer For A Total Consideration Of Up To $1B, Plus Tiered Royalties On Sales
Portfolio Pulse from Benzinga Newsdesk
Alexion, a subsidiary of AstraZeneca, has agreed to purchase and license a portfolio of preclinical gene therapy programs from Pfizer for a total consideration of up to $1B, plus tiered royalties on sales.
July 28, 2023 | 7:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's subsidiary Alexion's acquisition of Pfizer's gene therapy programs could potentially boost its future revenues and strengthen its position in the gene therapy market.
The acquisition of Pfizer's gene therapy programs by Alexion, a subsidiary of AstraZeneca, could potentially boost AstraZeneca's future revenues and strengthen its position in the gene therapy market. This could have a positive impact on AstraZeneca's stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Pfizer's sale of its preclinical gene therapy programs to Alexion could result in a short-term cash influx of up to $1B, plus potential future royalties.
Pfizer's sale of its preclinical gene therapy programs to Alexion could result in a short-term cash influx of up to $1B, plus potential future royalties. This could have a positive impact on Pfizer's stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80